SEC Filing Summary: Acasti Pharma Inc. (ACST)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Acasti Pharma Inc. on August 16, 2024, covering events occurring on August 12, 2024. The filing discloses the execution of a new employment agreement with Prashant Kohli, the Company's Chief Executive Officer. Note: The request metadata referenced "Grace Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Acasti Pharma Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation terms.
Material Changes and Executive Compensation
On August 12, 2024, the Company entered into a Letter Agreement with CEO Prashant Kohli. Key terms include:
- Base Salary: $500,000 annually.
- Discretionary Bonus: Up to 50% of the annual base salary, contingent on continued employment and Board determination.
- Equity Incentives: Potential stock options subject to Board approval, fair market value pricing, and continued employment.
- Termination Benefits: In the event of termination without Cause (including after a change of control), the CEO is entitled to 12 months of continued base salary, subject to a general release of claims.
- Restrictions: The agreement includes standard confidentiality, non-competition, and non-solicitation obligations.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific business risks beyond the standard contractual obligations of the employment agreement. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the exact terms of the stock option plan referenced in the agreement, as specific grant amounts are not detailed in this filing.
- Review the full text of the Letter Agreement (Exhibit 10.1) for detailed definitions of "Cause" and "Change of Control."
- Confirm the Company's current cash position to assess the ability to fund the potential 12-month severance obligation.
- Check for any subsequent filings regarding the actual grant of stock options to the CEO.